Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase




Tarveda Therapeutics to Present at Solebury Trout/BMO Private Company Showcase

WATERTOWN, Mass.–(BUSINESS WIRE)–Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, today announced that Brian Roberts, President and Chief Executive Officer, will present virtually at the Solebury Trout/BMO Fall 2021 Private Company Showcase on Thursday, October 14.

The presentation details are as follows:

Solebury Trout/BMO Fall 2021 Private Company Showcase

Date: Thursday, October 14

Time: 9:40am Eastern Time

Location: Virtual – register to attend

About Tarveda Therapeutics®, Inc.

Tarveda Therapeutics is a clinical stage biopharmaceutical company developing a new class of potent and selective precision oncology medicines, which it refers to as Pentarin® miniature drug conjugates, for the treatment of patients with various solid tumor malignancies. Tarveda’s Pentarin® miniature drug conjugates are designed to deeply penetrate solid tumors, selectively bind to the desired tumor targets and accumulate their anti-cancer payloads directly in tumor cells. The payload is retained and then released over time causing the anti-cancer payload to become active in the tumor.

Tarveda’s first clinical program, PEN-866, is the initial candidate from its Heat Shock Protein 90 (“HSP90”) binding miniature drug conjugate platform. HSP90 is a molecular chaperone that is highly activated in the harsh tumor environment, but which remains relatively dormant in normal tissue. Up to 75% of solid tumors have activated HSP90, and small molecule drugs that target activated HSP90 have desirable binding properties in solid tumors. PEN-866 is a miniature drug conjugate that selectively binds to the activated form of HSP90 linked to a topoisomerase 1 inhibitor (SN-38), a potent anti-cancer payload. PEN-866 has commenced its Phase 2a trial in various types of solid tumors. In addition to PEN-866, Tarveda is developing additional miniature drug conjugates on its HSP90 binding miniature drug conjugate platform to target other promising anti-cancer payloads such as kinase inhibitors and radioisotopes to solid tumors. For more information regarding Tarveda, go to: http://www.tarvedatx.com.

Contacts

Amanda Houlihan

MacDougall

781-235-3060

ahoulihan@macbiocom.com